Penumbra, Inc. $PEN Holdings Decreased by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P trimmed its holdings in shares of Penumbra, Inc. (NYSE:PEN) by 14.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 101,740 shares of the company’s stock after selling 17,804 shares during the period. Loomis Sayles & Co. L P’s holdings in Penumbra were worth $26,110,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Parkside Financial Bank & Trust boosted its position in Penumbra by 70.2% during the 2nd quarter. Parkside Financial Bank & Trust now owns 160 shares of the company’s stock worth $41,000 after acquiring an additional 66 shares during the period. AlphaQuest LLC acquired a new position in shares of Penumbra in the 1st quarter valued at about $66,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Penumbra in the first quarter worth approximately $76,000. Spire Wealth Management acquired a new stake in shares of Penumbra during the second quarter worth approximately $91,000. Finally, IFP Advisors Inc boosted its holdings in shares of Penumbra by 6,600.0% during the second quarter. IFP Advisors Inc now owns 670 shares of the company’s stock worth $172,000 after purchasing an additional 660 shares during the period. 88.88% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Penumbra

In other Penumbra news, Director Harpreet Grewal sold 186 shares of the company’s stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $227.58, for a total transaction of $42,329.88. Following the completion of the sale, the director owned 8,516 shares of the company’s stock, valued at $1,938,071.28. This represents a 2.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Adam Elsesser sold 15,800 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $269.65, for a total value of $4,260,470.00. Following the transaction, the chief executive officer owned 182,460 shares in the company, valued at approximately $49,200,339. This trade represents a 7.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 35,330 shares of company stock worth $9,932,319. 4.20% of the stock is currently owned by company insiders.

Penumbra Trading Down 0.9%

Penumbra stock opened at $293.17 on Friday. Penumbra, Inc. has a one year low of $221.26 and a one year high of $310.00. The company’s fifty day moving average price is $260.26 and its two-hundred day moving average price is $257.65. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.75 and a quick ratio of 4.04. The company has a market capitalization of $11.48 billion, a price-to-earnings ratio of 77.97, a PEG ratio of 2.10 and a beta of 0.51.

Penumbra (NYSE:PEN) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.97 earnings per share for the quarter, topping analysts’ consensus estimates of $0.90 by $0.07. The company had revenue of $354.69 million during the quarter, compared to analysts’ expectations of $340.77 million. Penumbra had a return on equity of 11.55% and a net margin of 11.54%.The business’s quarterly revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.85 earnings per share. Penumbra has set its FY 2025 guidance at EPS. On average, analysts forecast that Penumbra, Inc. will post 3.67 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Evercore ISI reiterated an “outperform” rating and issued a $286.00 price objective on shares of Penumbra in a research note on Thursday, November 6th. Wells Fargo & Company assumed coverage on shares of Penumbra in a research note on Tuesday, November 18th. They issued an “underweight” rating on the stock. Weiss Ratings reiterated a “hold (c+)” rating on shares of Penumbra in a report on Tuesday. BTIG Research restated a “buy” rating and issued a $320.00 target price on shares of Penumbra in a research note on Monday, October 27th. Finally, Wall Street Zen lowered Penumbra from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $305.69.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.